0001640455-18-000024.txt : 20180307
0001640455-18-000024.hdr.sgml : 20180307
20180307190036
ACCESSION NUMBER: 0001640455-18-000024
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180305
FILED AS OF DATE: 20180307
DATE AS OF CHANGE: 20180307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Trehu Elizabeth
CENTRAL INDEX KEY: 0001693456
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 18674626
MAIL ADDRESS:
STREET 1: C/O JOUNCE THERAPEUTICS, INC.
STREET 2: 1030 MASSACHUSETTS AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_152046722163949.xml
FORM 4
X0306
4
2018-03-05
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001693456
Trehu Elizabeth
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common Stock
2018-03-05
4
M
0
4545
4.02
A
4545
D
Common Stock
2018-03-05
4
S
0
3179
21.24
D
1366
D
Common Stock
2018-03-05
4
S
0
1366
22.11
D
0
D
Stock Option (Right to Buy)
4.02
2018-03-05
4
M
0
4545
0
D
2025-11-12
Common Stock
4545.0
246805
D
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades.
Represents the weighted average share price of an aggregate total of 3,179 shares sold in the price range of $20.86 to $21.70 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 1,366 shares sold in the price range of $21.98 to $22.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
25% of the option shares vested and became exercisable on November 3, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter.
/s/ Anna L. Barry, Attorney-in-Fact
2018-03-07